HALO:BMV
Halozyme Therapeutics, Inc.
MXN 1,955.00
arrow_downward
-0.70%(-13.69) 1H
1 Okt, 1:46:16 PTG GMT-6 · MXN
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk HALO...
Permodalan Pasaran
12.53B
Purata volum
440.00
Volum
0.00
tgi 52 mgu
MXN 1,970.00
rdh 52 mgu
MXN 1,121.86
Bilangan pekerja
423
Permodalan Pasaran
12.53B
Purata volum
440.00
Volum
0.00
tgi 52 mgu
MXN 1,970.00
rdh 52 mgu
MXN 1,121.86
Bilangan pekerja
423
Cerita berita
Daripada sumber web dan rakan kongsi berita
ChartMill
·
1 hari lalu
Halozyme Therapeutics (NASDAQ:HALO): A Decent Value Stock With Strong Profitability
Investing.com Nigeria
·
1 hari lalu
Form 4 Halozyme Therapeutics Inc For: 8 October By Investing.com
Investing.com Nigeria
·
1 hari lalu
Halozyme CEO Helen Torley sells $6.61m in shares By Investing.com
Yahoo Finance
·
2 hari lalu
Is Halozyme’s EU Injunction on Subcutaneous Keytruda Reshaping the Investment Case For Merck (MRK)?
Profil
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
Perihal Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Pekerja423
Diasaskan1998
Ibu pejabatSan Diego, California, Amerika Syarikat
Sektor-
Laman webhalozyme.com